Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries [clinicaltrials:NCT00185276]

Bio2RDF namespace

clinicaltrials

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00185276

identifiers.org URI

NCT00185276

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

365

NCT00185276 arm group 0a6e71b1034abcd1f2d32e915b9fecee [clinicaltrials_resource:NCT00185276/arm-group/0a6e71b1034abcd1f2d32e915b9fecee]

arm group [clinicaltrials_vocabulary:arm-group]

NCT00185276 arm group 3f237303121a9d19106f8a7fd915e494 [clinicaltrials_resource:NCT00185276/arm-group/3f237303121a9d19106f8a7fd915e494]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... ts of your X-ray angiography.

brief title [clinicaltrials_vocabulary:brief-title]

Magnevist® Injection Enhanced ...... Aorta and Peripheral Arteries

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:82b22479031bc0753a8f8fde7a41ca84]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:0c7fb6b61d28885f0681bba5ba315399]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:2e14894d405d9da22fa4e21eae15af6f]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:32a614d9f90b46f409b8796a20bf474e]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:4598e0901cd03338bb503164bb0c45a3]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:4d0a472c684f741daff230fb8a7124b6]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:65df9e0f270820c83f4b50a59359ff13]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:70e89e8da796496ee4a4e6ecf04abf10]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:753edc4dd96cf87da188a85c10e79e54]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:7d792453b27af73c4c268c6c08d30461]

Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease Image creation after injection - evaluation at blind read [clinicaltrials_resource:ecb8c378fee7060f0f9df56f807b1523]

completion date [clinicaltrials_vocabulary:completion-date]

2004-08-01T00:00:00Z

detailed description [clinicaltrials_vocabulary:detailed-description]

This study has previous ...... e sponsor of the trial.

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

eligibility for clinicaltrials:NCT00185276 [clinicaltrials_resource:7ad63cdffbad7167b28e278dcb0879e8]

eligibility [clinicaltrials_vocabulary:eligibility]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-10T00:00:00Z

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

Gadopentetate dimeglumine (Magnevist, BAY86-4882) [clinicaltrials_resource:dc9b4ab258df0e7d3d0c550e131a1a08]

intervention [clinicaltrials_vocabulary:intervention]

Gadopentetate dimeglumine (Magnevist, BAY86-4882) [clinicaltrials_resource:ed23f852b4a64108744abe1d861bc624]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Gadolinium DTPA [clinicaltrials_resource:c29f4434052bc5477d30a00257b707dc]

Gadobenic acid [clinicaltrials_resource:e81898d620bd08231615b686c7a2fded]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

is section 801 [clinicaltrials_vocabulary:is-section-801]

No

keyword [clinicaltrials_vocabulary:keyword]

Structural abnormalities of the infrarenal aorta and peripheral arteries

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-12-29T00:00:00Z

Bayer [clinicaltrials_resource:d4ff4823ac2f6adeccc0e9df435e2e20]

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

link [clinicaltrials_vocabulary:link]

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product [clinicaltrials_resource:084396fac4ae068b8942452cdbd754c6]

Click here and search for drug information provided by the FDA [clinicaltrials_resource:7a06845f49ed0040937032af97edab4d]

Click here and search for Bayer product results [clinicaltrials_resource:d215e28faaf9c1c9b3b68ddd3533b240]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00185276

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

official title [clinicaltrials_vocabulary:official-title]

Randomized, Multi-center Open ...... DSA) as Standard of Reference

org study id [clinicaltrials_vocabulary:org-study-id]

91,208

Bayer Study Director [clinicaltrials_resource:b1c1f90b6ec7129e1a428d16e9b32e7c]

overall official [clinicaltrials_vocabulary:overall-official]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:c4bc4f773ccbcd55cb9f2f3165c0e021]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

306,781

Bayer [clinicaltrials_resource:d4ff4823ac2f6adeccc0e9df435e2e20]

source [clinicaltrials_vocabulary:source]

start date [clinicaltrials_vocabulary:start-date]

2003-03-01T00:00:00Z

clinicaltrials:NCT00185276 study design [clinicaltrials_resource:83d514c2c3967ebf0e0a6261620703d4]

study design [clinicaltrials_vocabulary:study-design]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00185276

verification date [clinicaltrials_vocabulary:verification-date]

2014-12-01T00:00:00Z

identifier

clinicaltrials:NCT00185276